- content
Orexin-A may be therapeutic only when the intervention restores circadian phase and sleep architecture. Nighttime OX1R/OX2R antagonism could improve glymphatic clearance, whereas daytime orexin tone may support attention and synaptic function.
- evidence_cited
["Orexin biology should be tested with time-of-day dosing and sleep/circadian endpoints, not only cognitive behavior.", "Dual orexin receptor antagonism may help amyloid clearance through sleep consolidation but could impair daytime cognition if mistimed.", "Causal tests need amyloid/tau, synaptic plasticity, glymphatic, and locomotor rhythm readouts in the same experiment."]
- argument
Orexin-A may be therapeutic only when the intervention restores circadian phase and sleep architecture. Nighttime OX1R/OX2R antagonism could improve glymphatic clearance, whereas daytime orexin tone may support attention and synaptic function.
- evidence
{"consensus": ["Orexin biology should be tested with time-of-day dosing and sleep/circadian endpoints, not only cognitive behavior.", "Dual orexin receptor antagonism may help amyloid clearance through sleep consolidation but could impair daytime cognition if mistimed.", "Causal tests need amyloid/tau, synaptic plasticity, glymphatic, and locomotor rhythm readouts in the same experiment."], "dissent": ["The skeptic noted that orexin-A may worsen rather than rescue cognition in some AD models by increasing wakefulness and amyloid burden.", "The expert cautioned that sedating interventions must be separated from disease-modifying effects."]}